Table 3.
Eradication Rates According to the Duration of Bismuth-Quadruple Therapy
| Duration of bismuth-quadruple therapy | Negative point mutation | Positive point mutation A2142G |
Positive point mutation A2143G or double* |
|---|---|---|---|
| Per-protocol | |||
| 7-day quadruple | 1/1 (100.0) | 8/8 (100.0) | 84/93 (90.3)† |
| 14-day quadruple | 1/1 (100.0) | 1/1 (100.0) | 21/21 (100.0)† |
| Intention-to-treat | |||
| 7-day quadruple | 1/1 (100.0) | 8/9 (88.9) | 86/105 (81.9)‡ |
| 14-day quadruple | 1/1 (100.0) | 1/1 (100.0) | 23/23 (100.0)‡ |
Data are presented as number/total number (%).
*Double, both A2142G and A2143G; †Two patients who received 7-day quadruple therapy had poor compliance, and two patients who received 14-day quadruple had poor compliance; ‡p=0.024 for the intention-to-treat analysis between 7-day and 14-day quadruple therapies.